A study of abemaciclib in healthy volunteers
Treatments studied
This study tests how a medicine called abemaciclib is processed by the body in healthy people. It helps researchers understand the drug's effects and safety before it is used in patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in good overall health
- Your body mass index (BMI) must be between 18 and 32
- You must not be able to get pregnant or father a child
- You must not take any prescription or over-the-counter medications, including herbal supplements, for 2 weeks before the study
- You must be willing to avoid vigorous exercise, alcohol, caffeine, and smoking during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called AB102 in healthy people to see if it is safe and how the body processes it. It may help researchers understand the right dose for future studies.
This study tests a new investigational drug (BMS-986521) in healthy volunteers to see how safe it is and how the body processes it. It helps researchers decide if the drug can be tested in future studies.
This study looks at how the body handles the drug abemaciclib, and how it relates to severe diarrhea, which is a common side effect. It is for people with high-risk, hormone receptor positive breast cancer who have already had surgery. The goal is to better understand and possibly manage diarrhea, so you can stay on treatment.
This trial tests whether a higher dose of abemaciclib (a pill that helps stop cancer cells from growing) is safe and effective when used after surgery for early high-risk breast cancer. It is for people whose cancer is hormone receptor positive and HER2 negative, and who will take it along with endocrine therapy (hormone-blocking treatment).
This Phase 2 study tests abemaciclib, a targeted cancer medicine, in people with advanced solid tumors that have specific gene changes related to cyclin D or CDK4/6. The goal is to see how well it controls tumors when standard treatments don’t work or aren’t available.
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
Hear when a new Healthy Volunteers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.